BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37547578)

  • 21. Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report.
    Nazmunnahar ; Ahmed I; Islam MR
    Health Sci Rep; 2023 Mar; 6(3):e1127. PubMed ID: 36875932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies.
    Lusvarghi S; Pollett SD; Neerukonda SN; Wang W; Wang R; Vassell R; Epsi NJ; Fries AC; Agan BK; Lindholm DA; Colombo CJ; Mody R; Ewers EC; Lalani T; Ganesan A; Goguet E; Hollis-Perry M; Coggins SA; Simons MP; Katzelnick LC; Wang G; Tribble DR; Bentley L; Eakin AE; Broder CC; Erlandson KJ; Laing ED; Burgess TH; Mitre E; Weiss CD
    Sci Transl Med; 2022 May; 14(645):eabn8543. PubMed ID: 35380448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
    Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D;
    J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
    Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
    Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study.
    Mandl P; Tobudic S; Haslacher H; Karonitsch T; Mrak D; Nothnagl T; Perkmann T; Radner H; Sautner J; Simader E; Winkler F; Burgmann H; Aletaha D; Winkler S; Blüml S
    Ann Rheum Dis; 2022 Jul; 81(7):1017-1022. PubMed ID: 35304407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves.
    Doll MK; Waghmare A; Heit A; Levenson Shakoor B; Kimball LE; Ozbek N; Blazevic RL; Mose L; Boonyaratanakornkit J; Stevens-Ayers TL; Cornell K; Sheppard BD; Hampson E; Sharmin F; Goodwin B; Dan JM; Archie T; O'Connor T; Heckerman D; Schmitz F; Boeckh M; Crotty S
    JAMA Netw Open; 2023 Feb; 6(2):e231181. PubMed ID: 36853602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
    Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
    Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of vaccines on clinical characteristics of convalescent adult patients infected with SARS-CoV-2 Omicron variant: A retrospective study.
    Wang J; Dong H; Zhao J; Li T; Wang M; Zhou C; Mu H
    Front Microbiol; 2023; 14():1096022. PubMed ID: 37065120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of protection against SARS-CoV-2 Omicron BA.1 and Delta infections in fully vaccinated outpatients.
    Roy A; Saade C; Josset L; Clément B; Morfin F; Destras G; Valette M; Icard V; Billaud G; Oblette A; Debombourg M; Garrigou C; Brengel-Pesce K; Generenaz L; Saker K; Hernu R; Pozzetto B; Lina B; Trabaud MA; Trouillet-Assant S; Bal A
    J Med Virol; 2023 Aug; 95(8):e28984. PubMed ID: 37503561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence of SARS-CoV-2 neutralizing antibodies and anti-Omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic disease: an explanatory study in Japan.
    Yamaguchi Y; Nameki S; Kato Y; Saita R; Sato T; Nagao S; Murakami T; Yoshimine Y; Amiya S; Morita T; Okita Y; Kawasaki T; Fujimoto J; Ueda Y; Maeda Y; Watanabe A; Takamatsu H; Nishida S; Shima Y; Narazaki M; Kumanogoh A
    Lancet Reg Health West Pac; 2023 Mar; 32():100661. PubMed ID: 36569794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the mucosal and systemic antibody responses in Covid-19 recovered patients with one dose of mRNA vaccine and unexposed subjects with three doses of mRNA vaccines.
    Liu S; Tsun JGS; Fung GPG; Lui GCY; Chan KYY; Chan PKS; Chan RWY
    Front Immunol; 2023; 14():1127401. PubMed ID: 36793736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
    Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
    J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.
    Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X
    Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring algorithm of hospitalized patients in a medical center with SARS-CoV-2 (Omicron variant) infection: clinical epidemiological surveillance and immunological assessment.
    Chen CS; Jian MJ; Chang CK; Chung HY; Li SY; Lin JC; Yeh KM; Yang YS; Chen CW; Hsieh SS; Tang SH; Perng CL; Chang FY; Shang HS
    PeerJ; 2023; 11():e14666. PubMed ID: 36710871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
    Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
    Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.